about
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort studyIntegrated therapy for HIV and tuberculosisIntegrated therapy for HIV and cryptococcosisComparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian PatientsGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisPrevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance AssayGenome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rashRisk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B.A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational DatabaseCYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Factors associated with suboptimal adherence to antiretroviral therapy in Asia.Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific RegionThe impact of wild-type reversion on transmitted resistance surveillance.HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in AsiaAssociation between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.Surveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand.Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factorsRenal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimensCryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsHIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study.Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals.Aeromonas hydrophila sepsis with septic embolism and rhabdomyolysis in a chronic iron overload haemodialysis patient treated with deferoxamineSafety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.Sweet's syndrome: a reaction to non-tuberculous mycobacterial infections.Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure.Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand.Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational databaseTransmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia.Cryptococcosis in human immunodeficiency virus-negative patients.
P50
Q24811445-8D5DD6DD-7749-4D1B-A2A4-AF4E9494977EQ26749428-7EB23008-5DD4-41C2-A282-8A1136457E33Q28077707-A15725E1-5A3E-4F6B-9184-47D1710A3DFCQ28534376-5A967197-0632-4B80-BAB3-1F5067ECE33DQ28545866-71F4A401-A7E1-4EF4-A4B8-4FC5CA82391EQ28547717-864FB389-5098-4392-BEB0-4FC8B7159CE3Q28553024-DAE85920-9A1E-4C32-AC25-AF205266981BQ28943298-86CB053D-638E-4089-95FB-4961C388F430Q30379106-F9D6981E-2CDC-457C-9EC8-8C7F31727559Q31154688-2855C775-00AD-4E65-BF78-D412E7381413Q33277939-FCA319B3-70FA-4ACD-9E2F-4D3A5D27FD39Q33375532-E20B2826-11E8-4AD5-B8BF-506259FE80EDQ33433188-A969EA37-962B-4B4A-9327-B41A168E7790Q33623024-7A9087FB-6C92-41C8-8283-B60E1F08C669Q33626312-51ED16E5-55D2-4ADF-A501-FECE5DF6B24CQ33644568-1EC42FCE-E9B8-4FFA-BD0D-D24A966BE565Q33820125-F6A22650-5B09-4014-A870-FB73505D0AC8Q33873540-F7295F6E-6564-4FE8-BDF9-11A78929F79BQ34054047-37B71F53-BAD7-430B-9D94-A3866A4D627DQ34072721-8088C332-ACC7-401D-8EB4-CB4D080E5F95Q34092708-F19077EE-2DCF-498A-BC47-83810F6259A7Q34196792-DE34D56A-895B-4076-904B-6A94B4EE53F6Q34346783-33D8DA70-237B-40DB-B2F1-447820105ABDQ34457230-5011E050-261C-45CE-B666-6E211F0E6833Q34481581-07CB77CB-C66D-46EA-B9C4-72202279BCC7Q34488494-E54B7CFD-7C34-4F24-AE0A-579CDC275ECDQ34516548-2F6001C7-FF54-435B-BCE3-DDE4C55F0DE3Q34756828-49EE711F-2F1B-4F9C-97F6-8B40976B3D7DQ35111937-93BA43A7-1BBD-4F91-B3A2-E0374F886C4CQ35441596-5E860C74-5E0D-42C7-82E4-C9F14CB55300Q35573817-EDB6DC88-0206-4B2F-99B5-EF36554EC4CAQ35689833-A1EF245B-8AF2-47F9-A076-1D0208D0E123Q35820138-C7820853-A8BC-430C-926F-9EB4504FE2D3Q35832732-AFA9B13F-1E56-4705-B2A0-ACF9DE78BA64Q35866370-6B812D85-665A-4B56-AC39-BE9B2845E6E9Q35898696-A0C6BB9D-CB3D-4CE8-AFDC-52027D18467FQ35907897-5A74BB21-B149-41BB-8DA6-4BC6B1AED9EAQ35967212-F2357EF2-56DF-4430-891C-115E85C927AFQ36016676-940A6F62-9AD2-4B4C-B93B-DAE97F73189EQ36313440-321D803A-2FDA-459A-B857-90BBFAC5CCEE
P50
name
Somnuek Sungkanuparph
@en
Somnuek Sungkanuparph
@nl
type
label
Somnuek Sungkanuparph
@en
Somnuek Sungkanuparph
@nl
prefLabel
Somnuek Sungkanuparph
@en
Somnuek Sungkanuparph
@nl